AvertD and AvertD Buccal Sample Collection Kit
AutoGenomics, Inc. · Decision date May 20, 2026
What did the FDA approve?
FDA records P230032/S005 as a supplement to PMA P230032, with the supplement type “Normal 180 Day Track No User Fee”. The recorded decision is approval, dated May 20, 2026.
FDA approval order statement
Approval of the revised protocol for the post-approval study (PAS) referenced above. The PAS protocol has been submitted to comply with the conditions of approval outlined in our approval order for P230032.
- Regulatory pathway
- PMA supplement
- Supplement type
- Normal 180 Day Track No User Fee
- Clinical specialty
- Clinical Toxicology
- Decision date
- May 20, 2026
- FDA change category
- Postapproval Study Protocol
Regulatory record facts
- Identifier
- P230032/S005
- Regulatory pathway
- PMA supplement
- Applicant
- AutoGenomics, Inc.
- Product code
- QZH
- Decision code
- APPR
- Decision date
- May 20, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Opioid use disorder genetic risk variant detection system and collection kit.
- Applicant
- AutoGenomics, Inc.
- Product code
- QZH
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P230032/S003 · Related supplement
AvertD and AvertD Buccal Sample Collection Kit
P230032/S004 · Related supplement
AvertD and AvertD Buccal Sample Collection Kit
P230032/S005 received
Application receipt date recorded by FDA.
P230032/S005 · FDA decision
Normal 180 Day Track No User Fee
Timeline entries are records held by MedtechLedger for P230032. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P230032
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
AvertD and AvertD Buccal Sample Collection KitP230032/S003 | AutoGenomics, Inc. | PMA supplement | Jan 29, 2026 | FDA |
AvertD and AvertD Buccal Sample Collection KitP230032/S004 | AutoGenomics, Inc. | PMA supplement | Apr 10, 2026 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
AutoGenomics, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 1600 Faraday Ave., Carlsbad, CA, 92008
Sources and methodology
- Original FDA record: P230032/S005
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 21, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records
